We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
376
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-140
Closed -$567K
BLCM
377
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-12,009
Closed -$2.15M
SIOX
378
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-2,632
Closed -$272K
SRNE
379
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-2,275
Closed -$1.91M
AGTC
380
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-124,000
Closed -$1.63M
ENDP
381
DELISTED
Endo International plc
ENDP
– –
-50,658
Closed -$3.08M
RDUS
382
DELISTED
Radius Health, Inc.
RDUS
– –
-11,600
Closed -$733K
CSLT
383
CALL
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-1,065
Closed -$447K
ADXS
384
CALL
DELISTED
Advaxis Inc
ADXS
– –
-97
Closed -$1.49M
ADXS
385
DELISTED
Advaxis Inc
ADXS
– –
-5,713
Closed -$877K
ADXS
386
PUT
DELISTED
Advaxis Inc
ADXS
– –
-57
Closed -$872K
ADMS
387
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-76,717
Closed -$1.29M
MNTA
388
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-1,000
Closed -$1.64M
TTPH
389
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-4,059
Closed -$606K
DERM
390
DELISTED
Dermira, Inc.
DERM
– –
-190,000
Closed -$5.46M
ONCE
391
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-1,379
Closed -$5.75M
APDNW
392
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
– –
-63,310
Closed -$196K
APC
393
DELISTED
Anadarko Petroleum
APC
– –
-102,300
Closed -$6.18M
APC
394
PUT
DELISTED
Anadarko Petroleum
APC
– –
-1,023
Closed -$6.18M
HZNP
395
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-164,658
Closed -$3.26M
HZNP
396
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-1,658
Closed -$3.29M
VXZ
397
CALL
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
– –
-334
Closed -$1.74M
TSRO
398
DELISTED
TESARO, Inc.
TSRO
– –
-20,000
Closed -$802K
TSRO
399
PUT
DELISTED
TESARO, Inc.
TSRO
– –
-200
Closed -$802K
ECYT
400
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-26,423
Closed -$121K
13 14 15
16
17

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.